Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.

Oncotarget - 25 Apr 2017

Li Kaishu, Ouyang Leping, He Mingliang, Luo Ming, Cai Wangqing, Tu Yalin, Pi Rongbiao, Liu Anmin

Abstract excerpt

PURPOSE: Numerous studies have reported that glioma patients with isocitrate dehydrogenase 1(IDH1) R132H mutation are sensitive to temozolomide treatment. However, the mechanism of IDH1 mutations on the chemosensitivity of glioma remains unclear. In this study, we investigated the role and the potential mechanism of Nrf2 in IDH1 R132H-mediated drug resistance. METHODS: Wild type IDH1 (R132H-WT) and mutant IDH1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Dacarbazine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Multidrug Resistance-Associated Proteins

Share to NAD(P)H Dehydrogenase (Quinone)

Share to NF-E2-Related Factor 2

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 28427200
DOI: 10.18632/oncotarget.15868
PMCID: PMC5438698

Genes

IDH1
NQO1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.PMID 28427200Read ↗

Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.Semantic proximity Read ↗

IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.Semantic proximity Read ↗

IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.Semantic proximity Read ↗

Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.Semantic proximity Read ↗

Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-κB activation in a hypoxia-inducible factor 1-α dependent manner.Semantic proximity Read ↗

Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.Semantic proximity Read ↗

IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53.Semantic proximity Read ↗

IDH1 mutation diminishes aggressive phenotype in glioma stem cells.Semantic proximity Read ↗

Overexpression of isocitrate dehydrogenase-1R¹³²H enhances the proliferation of A172 glioma cells via aerobic glycolysis.Semantic proximity Read ↗

IDH1R132H mutation increases radiotherapy efficacy and a 4-gene radiotherapy-related signature of WHO grade 4 gliomas.Semantic proximity Read ↗

R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes.Semantic proximity Read ↗

IDH1(R132H) mutation increases U87 glioma cell sensitivity to radiation therapy in hypoxia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.